Bailey Tianheng (688506.SH): iza-bren (EGFR×HER3 dual antibody ADC) for the treatment of recurrent or metastatic esophageal squamous cell carcinoma was included in the priority review process

Zhitong Finance App News, Baili Tianheng (688506.SH) issued an announcement. Recently, the EGFR × HER3 dual antibody ADC (injectable iza-bren) independently developed by the company was included in the list of priority review varieties by the Drug Evaluation Center of the China Drug Administration (“CDE”). According to public information inquiries, iza-Bren is also the world's first EGFR×HER3 dual-antibody ADC to be included in the list of priority review varieties.